GEMA SA OF SPAIN RENAMED BIOCHEMIE

14 March 1994

Since the takeover of Spanish company Gema SA and its wholly-owned subsidiary Biochemie GmbH by Switzerland's Sandoz, its production facility in Les Franqueses has been continuously upgraded and expanded, and is now the main production unit for semi-synthetic penicillins within the Biochemie group. It is one of the largest manufacturing sites in the world for amino- and isoxazole penicillins, according to the company.

Now, to further improve the organization of the group and create a homogeneous branding of products in world markets, Gema has been renamed Biochemie SA. The group has three state of-the-art plants for making beta lactam, penicillin and cephalosporin located in Austria, Spain and Indonesia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight